Evidence mapPaperPMID 39633396Full record

ReviewMolecular neurodegeneration2024

Aging-associated sensory decline and Alzheimer's disease.

Suji Hong, Seung-Hyun Baek, Mitchell K P Lai, Thiruma V Arumugam, Dong-Gyu Jo

Abstract readReview
In one paragraph

Review in Molecular neurodegeneration, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 1 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Suji Hong *The School of Pharmacy, Sungkyunkwan University, Suwon, 16419, Republic of Korea.
Seung-Hyun Baek *The School of Pharmacy, Sungkyunkwan University, Suwon, 16419, Republic of Korea.
Mitchell K P LaiDepartment of Pharmacology, Yong Loo Lin School of Medicine, Singapore, 117600, Singapore.
Thiruma V ArumugamThe School of Pharmacy, Sungkyunkwan University, Suwon, 16419, Republic of Korea. g.arumugam@latrobe.edu.au.
Dong-Gyu JoThe School of Pharmacy, Sungkyunkwan University, Suwon, 16419, Republic of Korea. jodg@skku.edu.ORCID http://orcid.org/0000-0003-2271-1076

Funding

Ministry of Oceans and Fisheries 2021-KS211513National health and medical research council of Australia 2019100National Research Foundation of Korea NRF-2022R1I1A1A01072791National Research Foundation of Korea RS-2024-00345742National Research Foundation of Korea RS-2024-00399237
6 · The paper itself

Abstract

Multisensory decline is common as people age, and aging is the primary risk of Alzheimer's Disease (AD). Recent studies have begun to shed light on the possibility that age-related sensory decline could accelerate AD pathogenesis, or be a prodromal indicator of AD. Sensory impairments, specifically in taste and smell, often emerge before cognitive symptoms in AD, indicating their potential as early biomarkers. Olfactory dysfunction has been frequently associated with AD and may offer valuable insights into early detection. Hearing impairment is significantly associated with AD, but its causal impact on AD progression remains unclear. The review also discusses visual and tactile deficits in AD, including retinal thinning and changes in tactile perception, highlighting their links to disease progression. Focusing on molecular mechanisms, the review explores the roles of amyloid-β (Aβ) accumulation and tau protein pathology in sensory decline and their bidirectional relationship with AD. In summary, the evidence presented conclusively supports advocating for an integrated approach to understanding AD and sensory decline, to enhance early detection, implementing preventive strategies, and developing therapeutic interventions for AD. This approach underscores the significance of sensory health in addressing neurodegenerative diseases, particularly AD.

Indexed as

AgingAlzheimer DiseaseAmyloid beta-PeptidesDisease ProgressionHumansSensation DisordersAmyloid beta-PeptidesAgingAlzheimer's Disease (AD)Early biomarkersSensory impairments

Identifiers

PMID39633396
PMCPMC11616278

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.